Zymeworks Inc. Common Stock Market Cap ($1.79 Billion)
Market Cap & Net Worth: Zymeworks Inc. Common Stock (ZYME)
Zymeworks Inc. Common Stock market cap. Zymeworks Inc. Common Stock (NASDAQ:ZYME) has a market capitalization of $1.79 Billion ($1.79 Billion) as of November 5, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6340 globally and #2020 in its home market, demonstrating a 7.24% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Zymeworks Inc. Common Stock's stock price $30.94 by its total outstanding shares 74836534 (74.84 Million). Also see Zymeworks Inc. Common Stock (ZYME) cash flow conversion for how efficiently the company converts equity into cash flow.
Zymeworks Inc. Common Stock Market Cap History (2017–2026)
Zymeworks Inc. Common Stock market cap history from 2017 to 2026. Data shows growth from $568.24 Million to $2.32 Billion (9.53% CAGR). Check ZYME share price today for real-time trading data and today's change.
Index Memberships
Zymeworks Inc. Common Stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.07% | #178 of 976 |
|
NASDAQ Composite
IXIC
|
$40.12 Trillion | 0.00% | #710 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.10% | #106 of 263 |
Weight: Zymeworks Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Zymeworks Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Zymeworks Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore ZYME net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
14.36x
Zymeworks Inc. Common Stock's market cap is 14.36 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $568.24 Million | $51.76 Million | -$10.41 Million | 10.98x | N/A |
| 2018 | $1.10 Billion | $53.02 Million | -$36.56 Million | 20.72x | N/A |
| 2019 | $3.40 Billion | $29.54 Million | -$145.44 Million | 115.15x | N/A |
| 2020 | $3.54 Billion | $38.95 Million | -$180.55 Million | 90.80x | N/A |
| 2021 | $1.23 Billion | $26.68 Million | -$211.84 Million | 45.97x | N/A |
| 2022 | $588.22 Million | $412.48 Million | $124.34 Million | 1.43x | 4.73x |
| 2023 | $777.55 Million | $76.01 Million | -$118.67 Million | 10.23x | N/A |
| 2024 | $1.10 Billion | $76.30 Million | -$122.69 Million | 14.36x | N/A |
Competitor Companies of ZYME by Market Capitalization
Companies near Zymeworks Inc. Common Stock in the global market cap rankings as of November 5, 2026. Also see ZYME total assets for a full breakdown of the balance sheet.
Key companies related to Zymeworks Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #181 globally with a market cap of $130.90 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #373 globally with a market cap of $76.14 Billion USD.
- CSL Ltd (AU:CSL): Ranked #415 globally with a market cap of $67.74 Billion USD ( AU$95.74 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #503 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #181 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.90 Billion | $549.04 |
| #373 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $76.14 Billion | $930.67 |
| #415 | CSL Ltd | AU:CSL | $67.74 Billion | AU$197.34 |
| #503 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $258.38 |
Market Capitalization of Zymeworks Inc. Common Stock (2017–2026)
Market capitalization of Zymeworks Inc. Common Stock from 2017 to today. Between 2017 and today, Zymeworks Inc. Common Stock's market cap moved from $568.24 Million to $ 2.32 Billion, with a yearly change of 9.53%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $2.32 Billion | +17.51% |
| 2025 | $1.97 Billion | +79.85% |
| 2024 | $1.10 Billion | +40.90% |
| 2023 | $777.55 Million | +32.19% |
| 2022 | $588.22 Million | -52.04% |
| 2021 | $1.23 Billion | -65.32% |
| 2020 | $3.54 Billion | +3.96% |
| 2019 | $3.40 Billion | +209.67% |
| 2018 | $1.10 Billion | +93.33% |
| 2017 | $568.24 Million | -- |
End of Day Market Cap According to Different Sources
On Nov 5th, 2026 the market cap of Zymeworks Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.79 Billion USD |
| MoneyControl | $1.79 Billion USD |
| MarketWatch | $1.79 Billion USD |
| marketcap.company | $1.79 Billion USD |
| Reuters | $1.79 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Zymeworks Inc. Common Stock
Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. … Read more